BP
PRQR icon

Ballentine Partners’s ProQR Therapeutics PRQR Stock Holding History

Ballentine Partners’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-23,035
Closed -$61K – 981
2024
Q4 		$61K Buy
+23,035
New +$73.1K ﹤0.01% 865

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Ballentine Partners's PRQR Position: Q1 2025 in Review

Ballentine Partners sold out of ProQR Therapeutics (PRQR) in Q1 2025, closing a stake of 23,035 shares — an estimated $61K sold.

Ballentine Partners first reported a position in PRQR in Q4 2024 and held it in 1 quarter. The position peaked at $61K in Q4 2024. 65 funds tracked by Wall St. Rank hold PRQR as of Q1 2025.

  • Ballentine Partners reported no remaining ProQR Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ballentine Partners sold 23,035 ProQR Therapeutics shares in Q1 2025, an estimated $61K.
  • Ballentine Partners first reported a position in ProQR Therapeutics in Q4 2024 and held it in 1 quarter.
  • Ballentine Partners's ProQR Therapeutics position peaked at $61K in Q4 2024.
  • 65 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2025.

Based on Ballentine Partners's 13F filing for Q1 2025, filed 1 May 2025.